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Background 
The raised interstitial fluid pressure (IFP) in tumors hinders the penetration and uptake of cytotoxic 
drugs. Reduction of the IFP by anti-VEGF and/or anti-PDGFR therapy enhances delivery of systemic 
chemotherapy. It is unknown, whether these effects could also enhance intraperitoneal 
chemotherapy (IPC). 
Methods 
Bilateral subperitoneal injections of 1.5 x 106 HT-29 cells in 40 µl Matrigel were administered to 
Foxn1nu nude athymic mice (Harlan). On day 10 to 15, mice were administered either placebo, 
Imatinib (50 mg/kg daily), Pazopanib (100 mg/kg daily), or Bevacizumab (5 mg/kg 2x). At day 15, each 
mouse underwent an open IPC procedure with 150 mg/m² Oxaliplatin for 60’ at 37°C. Intraoperative 
measurements of tumor IFP (Samba Preclin®) and pO2 (Oxylite®) were performed. Tumor, blood, and 
perfusate samples were taken postoperatively. A second experiment made use of DCE-MRI on day 
14, 19 and 26 to assess tumor growth and microvascular permeability.  
Results 
Tumor IFP was significantly lower in the Bevacizumab and Pazopanib groups. Interestingly, the 
hypoxic fraction (pO2 <5 mmHg) was also significantly increased in the Bevacizumab group. Tumor 
size and blood Pt concentration did not differ. Tumor growth was delayed mainly in the Bevacizumab 
and Pazopanib groups. 
Conclusions 
Treatment with Bevacizumab and Pazopanib leads to a markedly reduced IFP in colorectal xenograft 
tumors. This effect may allow for deeper penetration and higher concentration of Oxaliplatin in 
peritoneal tumors. The increased tumor growth delay confirms the potential of possible combination 
therapy. IHC, Pt (LA-ICP-MS) and DCE-MRI (Mistar) analysis are currently ongoing.  
